Cannell & Co. Synaptogenix, Inc. Transaction History

Cannell & Co.

  • $3.01 Billion
  • Q4 2023

A detailed history of Cannell & Co. transactions in Synaptogenix, Inc. stock. As of the latest transaction made, Cannell & Co. holds 30,000 shares of SNPX stock, worth $93,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,000
Previous 30,000 -0.0%
Holding current value
$93,000
Previous $13,000 38.46%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 03, 2023
SELL
$1.02 - $181.75 $47,144 - $8.4 Million
-46,220 Reduced 60.64%
30,000 $34,000
Q4 2021

Feb 09, 2022
SELL
$8.38 - $13.72 $1,257 - $2,058
-150 Reduced 0.2%
76,220 $649,000
Q3 2021

Nov 10, 2021
BUY
$6.65 - $12.1 $507,860 - $924,077
76,370 New
76,370 $759,000

Others Institutions Holding SNPX

# of Institutions
1
Shares Held
30K
Call Options Held
0
Put Options Held
0
View Full List

About Synaptogenix, Inc.

SNPX Quotes by TradingView
  • Ticker SNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,840,630
  • Market Cap $21.2M
  • Description
  • Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...
More about SNPX
Track This Portfolio

Track Cannell & Co. Portfolio

Follow Cannell & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannell & Co., based on Form 13F filings with the SEC.

News

Stay updated on Cannell & Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email